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REMBRANDTThis review summarizes the cellular bases of the effects of NaCHOleate (2-hydroxyoleic acid; 2OHOA; Minerval)
against glioma and other types of tumors. NaCHOleate, activates sphingomyelin synthase (SGMS) increasing the
levels of cellmembrane sphingomyelin (SM) anddiacylglycerol (DAG) togetherwith reductions of phosphatidyl-
ethanolamine (PE) and phosphatidylcholine (PC). The increases in themembrane levels of NaCHOleate itself and
of DAG induce a translocation and overexpression of protein kinase C (PKC) and subsequent reductions of Cyclin
D, cyclin-dependent kinases 4 and 6 (CDKs 4 and 6), hypophosphorylation of the retinoblastoma protein, inhibi-
tion of E2F1 and knockdown of dihydrofolate reductase (DHFR) impairing DNA synthesis. In addition in some
cancer cells, the increases in SM are associatedwith Fas receptor (FasR) capping and ligand-free induction of ap-
optosis. In glioma cell lines, the increases in SM are associated with the inhibition of the Ras/MAPK and PI3K/Akt
pathways, in association with p27Kip1 overexpression. Finally, an analysis of the Repository of Molecular Brain
Neoplasia Data (REMBRANDT) database for glioma patient survival shows that the weight of SM-relatedmetab-
olism gene expression in glioma patients' survival is similar to glioma-related genes. Due to its low toxicity and
anti-tumoral effect in cell and animal models its status as an orphan drug for glioma treatment by the European
Medicines Agency (EMA) was recently acknowledged and a phase 1/2A open label, non-randomized study was
started in patients with advanced solid tumors including malignant glioma. This article is part of a Special Issue
entitled: Membrane Structure and Function: Relevance in the Cell's Physiology, Pathology and Therapy.
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vier B.V.1. Membrane lipid composition and cancer
Normal or pathological cellular functions are generally associated
with the activity of speciﬁc proteins. As a consequence, most therapeu-
tic molecules are targeted to bind these speciﬁc proteins to revert their
Fig. 1.Membrane lipid structures. Examples of the relationship between lipid shapes, intrinsic curvatures and lipid phases. A. Lipids with rectangular shapes (e.g. PC, SM) do not confer a
curvature strain forming lamellar phases. B. Lipidswith a bulky polar headand only one acyl chain (e. g. lisophospholipids) have an inverted cone shape inducing a positive curvature strain
inmembranes. They favor the formation ofmicelles or HI phases. C. Lipidswith a small polar head (e.g. PE, CHO,DAG) have amolecular shape that resembles a truncated cone. They induce
a negative curvature strain and favor the formation of inverted micelles and hexagonal HII phases. D. Examples of phospholipid-induced curvature strains in the membrane bilayer.
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(channels, receptors and enzymes) interact with lipids of the cell mem-
branes and these protein–lipid interactions are susceptible to be modi-
ﬁed, leading to changes in the protein activity [1]. In fact, changes in the
levels of lipids have beendescribed in a number of pathologies. For exam-
ple,modiﬁcations in the lipid composition or structure of cellmembranes
have been associated with the development of cardiovascular patholo-
gies, such as hypertension, atherosclerosis, coronary heart disease and
thrombosis [2–5].
Cancer cells show a constitutive activation of the fatty acid biosynthe-
sis to provide enough fatty acids to generate newmembranes due to the
increased proliferation ratio [6–8]. In this context, it has been demon-
strated that in breast tissue the fatty acid and phospholipid proﬁles are
altered not only in the tumor areas but also in the surrounding healthy
areas. This provides evidence that changes in phospholipid composition
can occur before the morphological tumoral changes [9]. Changes in the
lipid composition can also be related to the malignancy of the tumor.
For example, the pro-apoptotic ceramide is reduced in tumors and their
levels are inversely associated with tumor progression [10]. It is also
known that gangliosides, which act as immunosuppressors or as angio-
genesis promoters [11], are aberrantly distributed in a number of tumors[12]. Another important lipid pathwaymodiﬁed in cancer cells is choles-
terol (CHO) metabolism. Accumulation of esteriﬁed CHO levels are
associated with increased cell cycle progression and tumor growth [13].
In the last few years our group has accumulated evidence showing
the relationship between the plasma membrane sphingomyelin (SM)
levels and tumorigenesis. SM is synthesized by sphingomyelin synthase
(SGMS) which catalyzes the transfer of a phosphocholine head group
from a phosphatidylcholine (PC) to a ceramide yielding one diacylglyc-
erol (DAG) [14]. This process can occur in the Golgi apparatus mediated
by SGMS1 or in plasmamembrane by SGMS2 [15]. As SGSMs are able to
reverse the SM production forming again SM and DAG, they are consid-
ered regulators of proapoptotic ceramides andDAG as a secondmessen-
ger [16]. In this context, we have described that SM levels are reduced in
a variety of cancer cells compared to non-tumoral cells, and the restora-
tion of normal levels of SM by the activation of SGMS inhibits cell cycle
proliferation of cancer cells and/or induces cell death [16].
In this revision, we ﬁrst discuss how the lipids are organized in the
cell membrane and how lipids affect the cell signaling events involved
in different cancer-related processes. Therefore, lipid molecules could
be used as therapeutic molecules for the treatment of cancer. As an
example, we describe the mechanism of action of one of these lipid
1621V. Lladó et al. / Biochimica et Biophysica Acta 1838 (2014) 1619–1627drugs, NaCHOleate, a SGMS activator that has a promising potential in
cancer therapy.
2. How is the cell membrane organized?
In the 70s, a model for the cell plasma membrane structure where
lipids were distributed homogenously as a double layer was proposed.
This structure not only provided shape and protection to the cell but
also a ﬂuidic environment surrounding the embedded proteins [18].
Although nowadays the basic structure of this lipid bilayer is still accept-
ed,we know that lipids andproteins are not homogenously distributed in
the plasma membrane [19]. First, there is a heterogeneity or asymmetry
in the lipid composition of themembrane: the innermono-layer contains
a higher concentration of phosphatidylserine (PS) and phosphatidyletha-
nolamine (PE) whereas the extracellular mono-layer is enriched in PC
and SM [20]. An additional level of complexity and asymmetry is present
in lipid rafts, caveolae, receptors/channel clusters and synaptosomes
[21,22]. Evenmore, in a cell membrane there exists an enormous combi-
nation of lipid distributions due to the large amount of different lipid
species (about 1300–1500 on average), which allows lipophilic or elec-
trostatic interactions among each species permanently interchanging
their “partners” through lateral diffusion along the cell membrane [23].
Depending on the lipid composition, the lipids are organized in supra-
molecular structures that present characteristic biophysical properties,
such as ﬂuidity, electric charge, cross sectional area, lateral pressure
proﬁle, surface packing and non-lamellar-phase propensities (Fig. 1).
The most common lipid organization in the membrane is the
lamellar phase which can be subdivided in several types of lamellar
sub-structures. These sub-structures can change from one to another de-
pending of lipid composition, pH, ionic strength, temperature, water con-
centration or lateral pressure and the temperature that modulates the
ﬂuidity [24]. The lamellar α sub-structure (Lα), also known as ﬂuid
lamellar phase, liquid crystalline or liquid disordered (Ld), is the structure
found inmost domains and regions of the cellmembrane and shows high
levels of lipid and proteinmobility. This lamellar structure can evolve to a
variety of more organized structures, such as the gel phase (Lβ), pseudo-Fig. 2. NaCHOleate directly activates SMS. Upper-left panel, SMS activity is observed immedia
in vitro (bottom-left). Values represent the mean ± SEM; n = 3; *, p b 0.05; **, p b 0.01. The u
This ﬁgure was adapted from G. Barceló-Coblijn et al., Proc. Natl. Acad. Sci. U. S. A., 2011 Decemcrystalline (Lc), ripped (Pβ) membranes and the solid ordered (so or Lo)
[25]. The Lo phase is found in the lipid raft domains. Lipid rafts are
enriched in CHO and SM with the acyl chains of the lipids extended and
highly packed, but highly dynamic [26]. Essential cellular regulation pro-
cesses are compartmentalized in these CHO and SM raft domains [22,27].
CHO and other sterols, do not form a bilayer by themselves, but are im-
portant functional membrane components, by modifying the ﬂuidity
and organizing the Lo phases [28].
In addition to the lipids that form ﬂuid and organized lamellar
phases, the cell membrane includes the so-called non-lamellar-prone
lipids such as PE, CHO, DAG and acidic PS. These lipids are structurally
characterized by a non-cylinder shape that induces a curvature stress
into one of the layers of the cell membrane. If non-lamellar-prone lipids
are abundant, the membrane can adopt a conformation in which some
lipids adopt an extended shape with one of the acyl chain out of the
bilayer allowing a better access to the inner part of the cell membrane
[21]. The lipid curvature stress induced by the non-lamellar-prone lipids
can be organized into hexagonal and cubic phases among others [29].
For example, the DAG and PE induce negative curvature stress into the
cell membrane and can even form inverted hexagonal structure mono-
layers (HII) or invertedmicelles. The formation of HII phases is critical in
the budding, fusion and ﬁssion processes [30]. On the other hand, other
lipids with big polar heads as lysophospholipids induce positive curva-
ture strains in the membranes, forming normal hexagonal monolayers
(HI) or micelles.
The presence of these domains or the prevalence of one type of
phase in the membrane can direct the activation state and location of
a number of key membrane proteins as enzymes, receptors, channels
and effectors of a variety of cell signaling pathways.
G proteins and G protein-coupled receptors (GPCRs) are interesting
examples of protein activities modulated by membrane structure.
When the GPCRs are activated by their ligand, the signal is transmitted
by inducing the activation/dissociation of the heterotrimeric Gαβγ
proteins into the Gα and Gβγ subunits. Whereas the GPCRs and Gαβγ
have greater afﬁnity for Lε regions (with HII propensity), the Gα sub-
units are recruited in Lo regionswhere they interact with their effectors.tely after incubation with NaCHOleate, in intact U118 cells. This effect was also observed
pper-right panel shows the reaction catalyzed by SMS.
ber 6; 108 (49): 19569–19574 [17].
Fig. 3. Selective induction of SM levels in cancer cells by NaCHOleate. NaCHOleate induces a
marked increase of SM levels in human glioma (U118, 1321N1, SF767), lung cancer (A549)
and leukemia (Jurkat) cells, but not in normal cells. In this context, SM is found at very low
levels in all cancer cells studied and itsmembrane concentration is normalizedby treatments.
Values represent the mean ± SEM; n = 3; *, p b 0.05; ** p b 0.01; ***, p b 0.001.
This ﬁgure was adapted from G. Barceló-Coblijn et al., Proc. Natl. Acad. Sci. U. S. A.,
2011 December 6; 108 (49): 19569–19574 [17].
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where they interact with their own speciﬁc effectors and inactivate the
GPCRs [31–33]. Similarly, some isoforms of protein kinase C (PKC) are
activated by a non-lamellar lipid, such as PE and DAG, and translocate
to the membrane regions with propensity to form HII non-lamellar
phases [31]. Even more, inverted phases can induce the activation of
PKC by itself [34–36].
Another example is phospholipase C which once activated, converts
the phosphatidylinositol (PI) into inositol phosphate and DAG. Recent
studies have described how the inositol phosphate effectors, with the
FYVE peptide sequence that targets phosphatidyl inositol tri-phosphate
are accumulated in the inner layer of the membrane in PI enriched
domains [37].
The lipid rafts can also modify the activity of key proteins in cell
survival. For example, in conditions of increased synthesis of SM, the
FasR can be activated and trigger extrinsic apoptosis due to theFig. 4. NaCHOleate (72 h, 200 μM) induces changes in SF767 membrane-lipid composition.
Upper panel, levels of the major phospholipid classes before (black bars) and after (gray
bars) 2OHOA treatment: PC, phosphatidylcholine; PE, phosphatidylethanolamine;
SM, sphingomyelin; PS, phosphatidylserine; PI, phosphatidylinositol; LPC, lyso-
phosphatidylcholine. Lower panel, effects of NaCHOleate (72 h, 200 μM) on SM levels in nor-
mal (MRC5) and glioma (SF767) cells before (black) and after (gray) treatment (n = 6–8).
This ﬁgurewas adapted from S. Teres et al., Proc. Natl. Acad. Sci. U. S. A., 2012May 29; 109
(22): 8489–8494 [62].clustering of the receptor in the lipid rafts [38]. In addition, some
membrane-acting drugs as edelfosine, mitelfosine and NaCHOleate
can cluster and activate death receptors without the presence of their
ligand as will be discussed below [39,40].
Besides the differential afﬁnity of the intrinsic or interacting proteins
with the membrane, the membrane structure is also modulated by the
interaction with proteins. Several proteins have posttranscriptional
lipidmodiﬁcations that allow theprotein to interactwith themembrane
[41]. For example, the non-lamellar-phase binding propensity of Gγ
subunit is enhanced by the interaction of the membrane with the
isoprenyl moieties and with the transmembrane domain of membrane
receptors [42,43].
If we consider thatmost of the cancer-related pathways are, initially,
activated in the membrane and the lipid modiﬁcations occurring in
cancer cells are associated with the activation of proliferation and
tumorigenesis, it is conceivable that lipid modiﬁcations can regulate
these pathological cell signaling pathways.3. Membrane-lipid therapy
The membrane-lipid therapy is a novel therapeutic approach in
which the drugs are designed to target the membrane of diseased
cells,modulating its composition and structure and thereforemodifying
the activity ofmembrane-interacting proteins. These drugs are lipophilic
or amphiphilic molecules with the ability to change the general lipid
membrane organization and structure.
There are a number of natural lipid molecules that precisely
do so. For example, oleic acid increases the HII non-lamellar phase
propensity whereas its analogs, the trans-mono-unsaturated elaidic
acid and the saturated stearic acid, do not affect to the membrane
structure. This difference is because of their differences in the
shape of the molecule. While oleic acid presents a distinctive
“boomerang” shape, the elaidic and stearic acids have a “rod-
shape” that does not modify the membrane structure. Some of the
membrane-bound proteins that are known to be modulated by
oleic acid are the GPCRs, protein G and their effectors controlling
blood pressure [44–46]. In fact, a diet rich in olive oil (presents
high content of oleic acid) has been associated with a lower risk of
developing cancer [47].
Other natural lipids such as n-3 polyunsaturated fatty acids when
introduced in the organism by the diet, are readily inserted in the lipid
rafts displacing the CHO and provoking a de-clustering effect in the
lipid rafts, modifying the location of some intrinsic membrane proteins,
such as for example, the MHC class I proteins [48].
One of the ﬁrst evidences that antitumor drugs could act through
the membranes was the discovery that antracyclines do not need to
be internalized into the cell to exert its anti-tumoral function [49]. In
the past decade a number of othermolecules have shown to be effective
as an anti-cancer drug by targeting themembrane. For example, dauno-
rubicin and hexamethylene bisacetamide modify the nonlamellar HII
phase formation in the membrane [50,51]. In addition, hexamethylene
bisacetamide induces differentiation and cell cycle arrest of
erythroleukemia cells by reducing the DAG levels [52] and CHO
esteriﬁcation [13].
Alkylphospholipids belong to another class of drugs that target the
cell membrane. Among this class edelfosine, miltefosine and perifosine,
induce clustering and activation of Fas death receptor (FasR) through
structural changes of the lipid rafts [40,53].
Some anti-tumoral drugs have been recently modiﬁed by adding a
lipid motive in order to reduce the toxicity and/or increase its effective-
ness. For example, NEO6002, a gemcitabine derivate is modiﬁed by a
cardiolipin motive to reduce the toxicity and overcome the gemcitabine
resistance in cancer cells [54]. Another representative example is
propofol-DHA; the combination of the anesthetic propofol with the n-3
fatty acid induces apoptosis in breast cancer cells [55,56].
Fig. 5. Selective molecular and cellular effects of NaCHOleate on cancer cells. NaCHOleate
induces marked changes in the membrane levels of lipids that modify the interaction of
pivotal signaling proteins with membranes and their corresponding activities. The signaling
pathways regulated by these proteins are modiﬁed accordingly, resulting in induction of cell
cycle arrest, differentiation and autophagy or apoptosis in cancer but not normal cells.
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structure and function. Bactericidal peptides bind the membrane
altering its structure inducing anti-tumoral effects [57,58].4. Plasma membrane modiﬁcations by NaCHOleate
NaCHOleate was speciﬁcally designed to regulate the lipid composi-
tion and structure of the cell membrane (membrane lipid therapy).
Several years ago our group showed that NaCHOleate modiﬁed
plasmatic membrane composition and structure, altering the capacity
of different proteins to bind to the membrane and as a consequence
interfere with its activity [34,59].Table 1
Demographic and clinical characteristics of patients in REMBRANDT.
Variable Astrocytoma Gliob
N (%) n = 343 105 (30.6%) 181 (
Male, n (%) n = 249 54 (66.7%) 79 (6
Age, m ± SD n = 297 44.6 ± 14.8 55.2 ±
Grade, n (%) n = 247
Mild 0 (0%) 2 (1.9
Moderate 50 (53.2%) 0 (0%
Severe 44 (46.8%) 0 (0%
Very severe 0 (0%) 106 (
Race, n (%) n = 224
White 61 (91.0%) 114 (
Black 3 (4.5%) 2 (1.7
Other 3 (4.5%) 3 (2.5
Karnofsky baseline, m ± SD n = 160 87.4 ± 18.2 74.6 ±
Follow-up in months, m ± SD n = 343 50.1 ± 14.6 19.6 ±
REMBRANDT database (Glioma Molecular Diagnostic Initiative) contains gene expression a
glioblastoma, mixed and oligodendroglioma).NaCHOleate is incorporated in a variety of cancer cells faster than in
non-tumoral control ﬁbroblasts [60]. Moreover, the hydroxylation of
the fatty acids present in the phospholipid fraction of cell membranes
is increased after the treatment with NaCHOleate, indicating the incorpo-
ration of NaCHOleate in the glycerophospholipids of the cell [61]. The
NaCHOleate content in the total fatty acid in the glycerophospholipid frac-
tion is raised 15% after NaCHOleate treatment. Even more, NaCHOleate is
also incorporated in the triacylglyceride and DAG fraction of the neutral
lipid, but not into the sphingolipids. The above represent solid evidences
that NaCHOleate targets and it is incorporated into the cell membranes.
NaCHOleate treatment modiﬁes the composition, ﬂuidity and the
membrane lipid structure of cancer cells and other diseased cells [21].
For example, the treatment of hypertensive rats with NaCHOleate
lowers the blood systolic pressure to normal values and increases the
propensity of the membranes to form HII-phases [59].
It has been shown that in NaCHOleate-treated glioma cells the Ld
domains become more disordered, and conversely, the Lo domains
become more rigid and compact [17,61]. In this context, one of the
critical events triggered by NaCHOleate in cancer cell membrane is
the activation of SGMS (Fig. 2), increasing the SM levels in the mem-
brane (Figs. 3 and 4). These changes appear to be essential for the
antiproliferative effect of NaCHOleate in glioma cells [17,62].
In addition to the SGMSactivation, it has been shown thatNaCHOleate
decreases PE levels (Fig. 4), reduces oleic acid levels and increases saturat-
ed fatty acids incorporated in PC and PE in a number of cancer cells but
not in non-cancer cells (MRC5 human ﬁbroblasts) [61,62]. The reduction
of oleic acid levels can be explained by its substitution by NaCHOleate
and/or the inhibition of fatty acid biosynthesis by the effect ofNaCHOleate
in inhibiting stearoyl-CoA desaturase (SCD1) activity, an enzyme that
catalyzes a rate-limiting step in the synthesis of unsaturated fatty acids.
In summary NaCHOleate treatment induces a variety of changes in
membrane composition and in lipid metabolism enzymes modifying
the lipid structure and inducing the formation of different domains in
the cell membrane. For example, the increase in the order of the Lo
domains could be attributed to the changes in membranes levels of
SM and as a consequence the proportion of lipid rafts, with SM and
CHO as major components. As discussed, the lipid rafts are important
signaling platforms and their structure is sensitive to membrane lipid
composition as well as the activity proteins that interact in these do-
mains [63–65]. This decreased order of Ld domains can be associated
with a reduction in the surface lateral pressure of the lipid bilayer that
canmodify the binding and activity of some enzymes to themembrane,
such as PKC [34,66], and also activates SGMS and inhibits SCD1 [60,61].
Aswill be discussed next, a consequence of the above described changes
in the membrane structure and membrane-lipid enzymes is the inhibi-
tion of the proliferative signaling pathways in cancer cells.lastoma Mixed Oligodendroglioma Total
52.8%) 7 (2.0%) 50 (14.6%) 343 (100.0%)
1.7%) 4 (57.1%) 16 (48.5%) 153 (61.4%)
12.7 40.6 ± 6.9 47.1 ± 15.9 50.3 ± 14.6
%) 0 (0%) 0 (0%) 2 (0.8%)
) 2 (40.0%) 19 (47.5%) 71 (28.7%)
) 3 (60.0%) 21 (52.5%) 68 (27.5%)
98.1%) 0 (0%) 0 (0%) 106 (42.9%)
95.8%) 6 (85.7%) 29 (93.5%) 210 (93.8%)
%) 0 (0%) 1 (3.2%) 6 (2.7%)
%) 1 (14.3%) 1 (3.2%) 8 (3.6)
22.4 90.0 ± 10.9 80.8 ± 24.1 80.1 ± 21.8
18.5 52.7 ± 41.5 47.1 ± 55.9 33.6 ± 38.1
rrays, gene copy number arrays and clinical data of 343 glioma patients (astrocytoma,
Fig. 6. The levels of gene expression for SMS1 were down-regulated at least two-fold in 84
(24.5%) of 343 glioma samples. The survival on Kaplan–Meier plots of patients with gliomas
showed a signiﬁcant adverse association with the lower expression of SMS1 with p values
b0.0001. Green: glioma patients with normal SMS1 expression (n = 258); red: glioma
patients with low expression of SMS1 (n = 84).
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Glioma is the most common type of primary brain tumor and is
associated with very high rates of mortality and a high resistance to
chemotherapy and apoptosis induction [67]. The reference drug in
glioma treatment is temozolomide, an alkylating agent, which increases
the life expectancy of patients to about 2.5 months [68]. Due to the
promising anticancer effect of NaCHOleate in lung and leukemic cancer
cells and its lipid nature we decided to explore it as a treatment against
glioma. We have demonstrated that NaCHOleate is potentially more
effective than temozolomide using xenographicmicemodels.Moreover,
in contrast to temozolomide, there is no apparent relapse in the tumor
formation after treatment with NaCHOleate [62].Table 2
Expression of selected lipid and cancer genes in REMBRANDT.
Gene Down (n, %) Intermediate (n, %) Up (n, %)
Lipid ASAH2 115 (33.5%) 224 (65.3%) 4 (1.2%)
FASN 101 (29.4%) 234 (68.2%) 8 (2.3%)
SMPD2 0 (0%) 288 (84.0%) 55 (16.0%)
SMPD3 74 (21.6%) 269 (78.4%) 0 (0%)
PHYH 30 (8.7%) 311 (90.7%) 2 (0.6%)
SPTLC3 15 (4.4%) 197 (57.4%) 131 (38.2%)
SGMS1 84 (24.5%) 258 (75.2%) 1 (0.3%)
SGMS2 16 (4.7%) 254 (74.1%) 73 (21.3%)
SPHK1 6 (1.7%) 283 (82.5%) 54 (15.7%)
SPHK2 20 (5.8%) 292 (85.1%) 31 (9.0%)
UGCG 21 (6.1%) 283 (82.5%) 39 (11.4%)
Cancer AKT1 0 (0%) 317 (92.4%) 26 (7.6%)
AKT2 0 (0%) 285 (83.1%) 58 (16.9%)
AKT3 48 (14.0%) 291 (84.8%) 4 (1.2%)
MYC 4 (1.2%) 111 (32.4%) 228 (66.5%)
MAPK13 17 (13.7%) 288 (84.0%) 8 (2.3%)
PIK3CB 26 (7.6%) 317 (92.4%) 0 (0%)
PIK3CG 16 (4.7%) 235 (68.5%) 92 (26.8%)
PIK3CD 23 (6.7%) 313 (91.3%) 7 (2.0%)
NRAS 0 (0%) 236 (68.8%) 107 (31.2%)
kRAS 20 (5.8%) 322 (93.9%) 1 (0.3%)
TNF 34 (9.9%) 294 (85.7%) 15 (4.4%)
Analysis of the expression of eleven representative genes related to lipid metabolism and
eleven genes related to glioma from the data of gene expression arrays taken from the
REMBRANDT database (Glioma Molecular Diagnostic Initiative). Genes are listed with
standard abbreviations. Down: 2-fold survival belowaverage. Intermediate: average survival.
Up: 2-fold survival above average.6. Mechanism of action of the antiproliferative effect of NaCHOleate
We have demonstrated that NaCHOleate is effective in inducing cell
cycle arrest in lung cancer cells [69,70], apoptosis in several cancer cell
lines, including leukemic cancer cells [69,70], and ER stress, autophagy
and sphingomielidosis in glioma cell lines [62,71]. NaCHOleatemodiﬁes
the membrane composition, enhancing the propensity to induce the
non-lamellar HII phases in the membrane [34,59]. This correlates with
PKC translocation to the membrane with its concomitant activation,
inducing the activation/overexpression of p21Cip1 and p27Kip1,members
of CDKI family [34,62,72]. The NaCHOleate-induced overexpression of
CDKIs inhibits the formation of cyclin D–CDK4/6 complexes which are
associated with the hypophosphorylation of Rb [34,62,71,72]. E2F1 is a
transcription factor that induces the expression of proteins related
to the cell cycle progression and its regulation is dependent of the
Rb-phosphorylation status, being recruited and inactivated when
Rb is hypophosphorylated. One of E2F1 target genes is dihydrofolate
reductase (DHFR), essential for the synthesis of DNA, which is down-
regulated in a variety of NaCHOleate-treated cancer cell lines [62,70].
In Jurkat cells, the membrane modiﬁcations induced by NaCHOleate
facilitate the FasR capping without ligand binding, probably due to the
induction of lipid raft domains in the membrane. The FasR capping by
itself is able to trigger caspase activation [40] that, together with the
DHFR down-regulation, induces apoptosis in these cells [39,70].
In addition to the activation of PKC and FasR in the membrane of
NaCHOleate-treated cancer cells, modiﬁcations in the interaction of
Ras to the membrane have been identiﬁed as well. Ras is a family of
peripheral proteins that binds to membrane through its bulky isoprenyl
moiety in domains with high levels of PE and is constitutively activated
in many types of cancers. The restoration of SM levels and reduction of
PE in the membrane of NaCHOleate-treated glioma cells, exclude Ras
proteins from the plasma membrane [62]. In this context, NaCHOleate
has a similar effect to that of farnesyl transferase inhibitors, such as
tipifranib, which has an anti-cancer effect that is based on the impair-
ment of the binding of Ras to the membrane by inhibiting Ras
isoprenylation [73]. This Ras exclusion from the membrane inhibits the
activation of the different downstream pathways triggered by Ras, such
as MAPK and PI3K/Akt pathways [62]. MAPK as well as PI3K/Akt path-
ways are related with the loss of cellular differentiation and the survival
of cancer cells [74–76]. In fact, NaCHOleate treatment in glioma cancer
cells enhances the expression of markers of differentiation, such as glial
ﬁbrillary acidic protein (GFAP) and glutamine synthase (GS) [62]. The
overexpression of thesemarkers in cells exposed toNaCHOleate suggests
an induction of differentiation afterDHFRdownregulation, through PKC–
p21–CyclinD/CDK4/6–Rb pathway and Ras–MAPK and Ras–PI3K/Akt
pathway inhibition (Fig. 5) [18,62]. NaCHOleate activates the ceramide
synthesis and the recycling pathways of lipid metabolism with accumu-
lation of SM, ceramide and hexosylceramide species, resulting in
sphingolipidosis, compromising cell viability [60,62] and inducing au-
tophagy in glioma cells [71]. The autophagy induction in glioma cells is
related to the activation of the ER stress pathway in glioma cells and
cell cycle arrest in G2/M phase [71]. Due to its anti-tumoral effect in
cell and animal models and low toxicity NaCHOleate was recently ac-
knowledged the status of orphan drug for glioma treatment by the
EMA and a phase 1/2A open label, non-randomized study in patients
with advanced solid tumors including malignant glioma was started
[77].
7. The role of lipid metabolism genes in brain cancer
The alterations in lipid composition and in enzymes involved in lipid
metabolism are beginning to be associatedwith tumorigenesis and can-
cer patient survival. For example, a recent study demonstrated that
some lipid metabolism genes, such as, OLR1, GLRX, and SNAP23, are
co-ordinately upregulated in transformed cells and late-stage breast
and prostate cancer tissues [78]. In addition, some hepatic lipase
Table 3
Combination distribution of lipid and cancer genes altered in REMBRANDT.
Number
of lipid genes altered
Number of cancer
genes altered
N (%) Median survival
(months)
P Survival
(one year)
Survival
(three years)
Survival
(ﬁve years)
Survival
(ten years)
1 — Low risk b2 b2 104 (30.3%) 30.8 Ref. 0.57 0.34 0.20 0.08
2 —Medium risk lipid N3 b2 42 (12.2%) 14.6 0.068 0.40 0.26 0.17 0.10
3 —Medium risk cancer b2 N3 83 (24.2%) 22.6 0.144 0.48 0.22 0.13 0.04
4 — High risk N3 N3 114 (33.2%) 13.2 b0.001 0.20 0.10 0.04 0.01
All 343 (100.0%) 18.5 0.41 0.22 0.13 0.05
Median glioma patient survival analysis fromdata taken fromREMBRANDTdatabase (GliomaMolecular Diagnostic Initiative). Patients were divided in low risk,medium risk and high risk
categories depending of the number of genes (lipid and cancer) altered. Ref.: Reference group; the P values were calculated with respect to the Reference group.
Fig. 7. Diagram graph showing the frequency distribution (%) of lipid metabolism related
genes (ﬁlled bars) and consensus glioma cancer genes (white bars) whose expression is
altered in patients as shown in the REMBRANDT glioma database.
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[79]; and, it has been described that different enzymes related to fatty
acid biosynthesis and lipid metabolism regulation, such as, ACACA,
FASN, INSIG1, and SREBP1 are highly expressed in breast cancer tumors
and associatedwith low patient survival [80]. In this context, the Cancer
Genome Atlas (TCGA) database analysis for 38 ovarian cancer samples
demonstrated 39 differentially expressed lipid genes in ovarian cancer
tissue compared to normal ovarian tissues [81].
The role of lipid metabolism genes in brain cancer patient survival is
largely unknown. The REMBRANDT database is a suitable data source to
explore the potential role of genes to modify the prognosis of individ-
uals with brain cancer [82,83]. We have used this database as an addi-
tional source to investigate the relevance of lipid metabolism genes in
the survival of patients with glioma. It includes demographic, clinical
and genotype information of a cohort of glioma patients. To date,
REMBRANDT contains data generated through the Glioma Molecular
Diagnostic Initiative from glioma specimens comprising approximately
566 gene expression arrays, 834 copy number arrays, and13,472 clinical
phenotype data points. Overall, 343 glioma patients were included in
our study (Table 1). As a representative example of a lipid metabolism
gene we ﬁrst studied the expression of SGMS1 (which we have previ-
ously demonstrated as being activated by NaCHOleate) in the clinical
outcome of glioma (Fig. 6). Haplotype frequencies were produced for
down-regulated (n = 84) and normally expressed (n = 258) SMGS1.
Survival of patients with the up-regulation of SGMS1 expression was
not studied given its low proportion (n = 1). Frequency distributions
were obtained and survival was assessed using standard Kaplan–
Meier statistics and survival differences were quantiﬁed with Log
Rank (Mantel–Cox) tests, and the median follow-up time to death
[84]. In all analyses, a p value lower than 0.05 was considered for statis-
tical signiﬁcance. We found that at least two-fold down-regulation of
SMGS1 lowered very signiﬁcantly the median of survival of patients
with glioma. Moreover, the 10-year survival of patients with low
SGMS1 expression was ca. 10-fold lesser than that of patients with
normal SGMS1 expression. This result is in concordance with the
mechanism of action of NaCHOleate described above and supports the
hypothesis that the administration of NaCHOleate, a speciﬁc activator
of SGMS1,may reverse the low survival of glioma patients.We extended
this analysis to eleven representative genes related to lipid metabolism
and we compared the survival analysis to a set of eleven glioma
cancer-related genes (Table 2) [62,85,86]. When grouping samples
by the number of lipid metabolism and consensus cancer genes altered,
the average number of genes altered among the indicated list was 2.6±
1.8 vs. 2.9 ± 1.7 respectively (p = 0.432) so that no differences were
found. These data highlight the importance of SM and other lipid
metabolismgenes in themalignant transformation.Moreover, alterations
in genes related to lipid metabolism induce a regulation in the median
glioma patient survival from 22.6 months to 14.6 months (Table 3),
further supporting the relevance of membrane lipids in the cell physiolo-
gy and glioma etiopathology. According to an arbitrary threshold of 3
genes altered, based on the data shown in Fig. 7, REMBRANDT partici-
pants were stratiﬁed as those with genetic low risk (each ≤2 lipid and
cancer genes), thosewithmedium risk (only one set of genes≥3 altered)or thosewith high risk (each≥3 lipid and cancer genes). Median survival
in those with≥3 lipid genes alteredwas 13.2 months, signiﬁcantly lesser
than those of patients with≤2 lipid genes alteredwith amedian survival
of 30.8 months (p b 0.001). This result was independently associated
with death when compared to other glioma patients with an increasing
number of cancer genes altered, with a median of 15.0 months (≥3
lipid genes) and 13.2 (≥3 lipid genes and ≥3 cancer genes altered). To
our knowledge, this is the ﬁrst assessment of the study of lipid metabo-
lism genes in REMBRANDT and elsewhere. Lipid-related genotypes may
help to predict survival in glioma patients, and their effect appears inde-
pendent of the number of cancer genes altered. In addition, themolecular
features of tumorsmaybe relevant for patient stratiﬁcation and treatment
selection. In this context, companies such as Lipopharma Therapeutics
and Ability Pharmaceuticals are developing molecules for the regulation
of the membrane lipid composition and structure.
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